Westwood Holdings Group Inc. raised its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 4.5% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 171,274 shares of the company’s stock after purchasing an additional 7,309 shares during the quarter. Westwood Holdings Group Inc.’s holdings in Zoetis were worth $29,692,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Webster Bank N. A. increased its stake in Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the period. Neo Ivy Capital Management acquired a new position in shares of Zoetis during the 4th quarter worth $40,000. LRI Investments LLC acquired a new position in shares of Zoetis during the 1st quarter worth $43,000. Hazlett Burt & Watson Inc. increased its stake in shares of Zoetis by 60.7% during the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares during the last quarter. Finally, Central Valley Advisors LLC acquired a new position in shares of Zoetis during the 2nd quarter worth $49,000. Institutional investors and hedge funds own 92.80% of the company’s stock.
Zoetis Stock Performance
NYSE ZTS opened at $192.64 on Friday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a market capitalization of $87.90 billion, a price-to-earnings ratio of 37.12, a P/E/G ratio of 2.98 and a beta of 0.88. The company’s fifty day moving average is $184.70 and its two-hundred day moving average is $174.40. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.
Analyst Ratings Changes
Several brokerages have recently commented on ZTS. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $220.38.
Read Our Latest Research Report on Zoetis
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Read More
- Five stocks we like better than Zoetis
- 5 Top Rated Dividend Stocks to Consider
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Business Services Stocks Investing
- MarketBeat Week in Review – 9/16 – 9/20
- Top Stocks Investing in 5G Technology
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.